A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

NCT03795558 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease

Interventions

DRUG: Etelcalcetide

Sponsor

Prim. Priv. Doz. Dr. Daniel Cejka

Collaborators

[object Object]